Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1180-1191

  Van Hensbergen, Yvette ^a   Broxterman, Henk J ^a   Rana, Sareena ^a   Van Diest, Paul J ^a   Duyndam, Monique C A ^a   Hoekman, Klaas ^a   Pinedo, Herbert M ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; MICROSOMAL AMINOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; MUCINOUS CARCINOMA; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AMINOPEPTIDASES; ANIMALS; ANTIGENS, CD13; APOPTOSIS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; CISPLATIN; COLLAGEN; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PLASMIDS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S PHASE; TIME FACTORS; TRANSFECTION;

EID: 1042266693     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0482-3     Document Type: Article

References (44)

1. Serov, S. F., Scully, R. E., and Sobin, L. H. Histological Typing of Ovarian Tumours. International Histological Classification of Tumours, 9th ed., pp. 17-54. Geneva: WHO, 2003.
2. Kristiansen, G., Denkert, C., Schluns, K., Dahl, E., Pilarsky, C., and Hauptmann, S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol., 161: 1215-1221, 2002.
3. Sood, A. K., Fletcher, M. S., Gruman, L. M., Coffin, J. E., Jabbari, S., Khalkhali-Ellis, Z., Arbour, N., Seftor, E. A., and Hendrix, M. J. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res., 8: 2924-2932, 2002.
4. Kajiyama, H., Kikkawa, F., Suzuki, T., Shibata, K., Ino, K., and Mizutani, S. Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res., 62: 2753-2757, 2002.
5. Bordessoule, D., Jones, M., Gatter, K. C., and Mason, D. Y. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66, and CD67. Br. J. Haematol., 83: 370-383, 1993.
6. Mechtersheimer, G., and Moller, P. Expression of aminopeptidase N (CD13) in mesenchymal tumors. Am. J. Pathol., 137: 1215-1222, 1990.
7. Alliot, F., Rutin, J., Leenen, P. J., and Pessac, B. Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin. J. Neurosci. Res., 58: 367-378, 1999.
8. Dixon, J., Kaklamanis, L., Turley, H., Hickson, I. D., Leek, R. D., Harris, A. L., and Gatter, K. C. Expression of aminopeptidase-N (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J. Clin. Pathol., 47: 43-47, 1994.
9. Hashida, H., Takabayashi, A., Kanai, M., Adachi, M., Kondo, K., Kohno, N., Yamaoka, Y., and Miyake, M. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology, 122: 376-386, 2002.
10. Ishii, K., Usui, S., Sugimura, Y., Yoshida, S., Hioki, T., Tatematsu, M., Yamamoto, H., and Hirano, K. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int. J. Cancer, 92: 49-54, 2001.
11. Ishii, K., Usui, S., Yamamoto, H., Sugimura, Y. Tatematsu, M., and Hirano, K. Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J. Biochem., 129: 253-258, 2001.
12. Fujii, H., Nakajima, M., Aoyagi, T., and Tsuruo, T. Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors. Biol. Pharm. Bull., 19: 6-10, 1996.
13. Saiki, I., Fujii, H., Yoneda, J., Abe, F., Nakajima, M., Tsuruo, T., and Azuma, I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer, 54: 137-143, 1993.
14. Fujii, H., Nakajima, M., Saiki, I., Yoneda, J., Azuma, I., and Tsuruo, T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin. Exp. Metastasis, 13: 337-344, 1995.
15. Bhagwat, S. V., Lahdenranta, J., Giordano, R., Arap, W., Pasqualini, R., and Shapiro, L. H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 97: 652-659, 2001.
16. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60: 722-727, 2000.
17. van Hensbergen, Y., Broxterman, H. J., Hanemaaijer, R., Jorna, A. S., Van Lent, N. A., Verheul, H. M., Pinedo, H. M., and Hoekman, K. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin. Cancer Res., 8: 3747-3754, 2002.
18. Benard, J., Da Silva, J., De Blois, M. C., Boyer, P., Duvillard, P., Chiric, E., and Riou, G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res., 45: 4970-4979, 1985.
19. Graham, F. L., and van der Eb, A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52: 456-467, 1973.
20. van Hensbergen, Y., Broxterman, H. J., Elderkamp, Y. W., Lankelma, J., Beers, J. C., Heijn, M., Boven, E., Hoekman, K., and Pinedo, H. M. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem. Pharmacol., 63: 897-908, 2002.
21. Favaloro, E. J. CD-13 (gp150; aminopeptidase-N): co-expression on endothelial and haemopoietic cells with conservation of functional activity. Immunol. Cell Biol., 69: 253-260, 1991.
22. Wellmann, S., Taube, T., Paal, K., Graf, V. E., Geilen, W., Seifert, G., Eckert, C., Henze, G., and Seeger, K. Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin. Chem., 47: 654-660, 2001.
23. Kolfschoten, G. M., Hulscher, T. M., Pinedo, H. M., and Boven, E. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br. J. Cancer, 83: 921-927, 2000.
24. Bergers, E., van Diest, P. J., and Baak, J. P. Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J. Clin. Pathol., 49: 931-937, 1996.
25. Bergers, E., Baak, J. P., van Diest, P. J., Willig, A. J., Los, J., Peterse, J. L., Ruitenberg, H. M., Schapers, R. F., Somsen, J. G., van Beek, M. W., Bellot, S. M., Fijnheer, J., and van Gorp, L. H. Prognostic value of DNA ploidy using flow cytometry in 1301 breast cancer patients: results of the prospective Multicenter Morphometric Mammary Carcinoma Project. Mod. Pathol., 10: 762-768, 1997.
26. 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line IGROV 1 on the human umbilical vein cell extracellular matrix. Int. J. Cancer, 99: 800-808, 2002.
27. Skubitz, A. P. Adhesion molecules. Cancer Treat. Res., 107: 305-329, 2002.
28. Brekken, R. A., Puolakkainen, P., Graves, D. C., Workman, G., Lubkin, S. R., and Sage, E. H. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Investig., 111: 487-495, 2003.
29. Riemann, D., Kehlen, A., and Langner, J. CD13: not just a marker in leukemia typing. Immunol. Today, 20: 83-88, 1999.
30. Boonacker, E., and Van Noorden, C. J. The multifunctional or moonlighting protein CD26/DPPIV. Eur. J. Cell Biol., 82: 53-73, 2003.
31. Navarrete, S. A., Roentsch, J., Danielsen, E. M., Langner, J., and Riemann, D. Aminopeptidase N/CD13 is associated with raft membrane microdomains in monocytes. Biochem. Biophys. Res. Commun., 269: 143-148, 2000.
32. Antczak, C., De, M. I., and Bauvois, B. Ectopeptidases in pathophysiology. Bioessays, 23: 251-260, 2001.
33. Frank, P. G., Woodman, S. E., Park, D. S., and Lisanti, M. P. Caveolin, caveolae, and endothelial cell function. Arterioscler. Thromb. Vasc. Biol., 23: 1161-1168, 2003.
34. Kajiyama, H., Kikkawa, F., Khin, E., Shibata, K., Ino, K., and Mizutani, S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res., 63: 2278-2283, 2003.
35. Kohn, E. C., Fidler, I. J., Fishman, D., Jaffe, R., Liotta, L. A., van Trappen, P., Mills, G. B., and Trope, C. Discussion: metastasis and angiogenesis in epithelial ovarian cancer. Gynecol. Oncol., 88: S37-S42, 2003.
36. Mills, G. B., Fang, X., Lu, Y., Hasegawa, Y., Eder, A., Tanyi, J., Tabassam, F. H., Mao, M., Wang, H., Cheng, K. W., Nakayama, Y., Kuo, W., Erickson, J., Gershenson, D., Kohn, E. C., Jaffe, R., Bast, R. C., Jr., and Gray, J. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol. Oncol., 88: S88-S92, 2003.
37. Fujiwara, H., Imai, K., Inoue, T., Maeda, M., and Fujii, S. Membrane-bound cell surface peptidases in reproductive organs. Endocr. J., 46: 11-25, 1999.
38. Hoffmann, T., Faust, J., Neubert, K., and Ansorge, S. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett., 336: 61-64, 1993.
39. Rosenzwajg, M., Tailleux, L., and Gluckman, J. C. CD13/N-aminopeptidase is involved in the development of dendritic cells and macrophages from cord blood CD34(+) cells. Blood, 95: 453-460, 2000.
40. Drevs, J., Muller-Driver, R., Wittig, C., Fuxius, S., Esser, N., Hugenschmidt, H., Konerding, M. A., Allegrini, P. R., Wood, J., Hennig, J., Unger, C., and Marme, D. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res., 62: 4015-4022, 2002.
41. Bevan, J. A., and Laher, I. Pressure and flow-dependent vascular tone. FASEB J., 5: 2267-2273, 1991.
42. Loufrani, L., Levy, B. I., and Henrion, D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ. Res., 91: 1183-1189, 2002.
43. Griffon-Etienne, G., Boucher, Y., Brekken, C., Suit, H. D., and Jain, R. K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res., 59: 3776-3782, 1999.
44. Netti, P. A., Roberge, S., Boucher, Y., Baxter, L. T., and Jain, R. K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc. Res., 52: 27-46, 1996.